Neurovirt

XR solution transforming rehabilitation with engaging therapy, precise compensation control, and accurate remote monitoring

Dr. Eve Gregoriou, Founder & CEO NeuroVirt Limited

NeuroVirt is a digital health company using extended reality (Virtual and Augmented Reality) to transform neurorehabilitation for stroke and other neurological patients. The innovation tackles a critical NHS challenge: the shortage of intensive, high-quality rehabilitation - particularly following stroke - where national guidelines recommend three hours of daily therapy, a target most services currently cannot meet due to workforce and capacity constraints.

The innovation gamifies rehabilitation through immersive, individualised XR environments that engage patients in enjoyable, evidence-based therapy. NeuroVirt’s proprietary algorithms detect and correct for non-optimal movement patterns in real-time, ensuring high-quality therapy delivery. Clinicians can remotely monitor detailed recovery data and prescribe personalised exercises via the NeuroVirt app, enabling scalable rehabilitation across home and clinical settings. With just one device, NeuroVirt supports intensive training of both upper and lower limbs, addressing a full spectrum of motor impairments.

NeuroVirt increases therapy intensity by up to 15 times, reduces clinician burden, and supports earlier discharge from inpatient care, easing bed pressures and expanding access to community-based rehabilitation. Patients using NeuroVirt at home show dramatic increases in adherence, with 87% reporting improved confidence or function. NeuroVirt enables faster, data-driven decision making, with detailed digital assessments completed in under 1 minute and remote monitoring tools that allow clinicians to personalise care in real time.

By providing equitable access to gold-standard therapy - including to underserved or rural populations - and reducing travel-related emissions, NeuroVirt also supports the NHS’s health equity and Net Zero goals. The innovation enhances productivity, relieves system bottlenecks, and ensures that every patient can access the intensity of rehabilitation they need to recover.

• Over 500 neurological patients benefited
• Increases rehabilitation intensity by 15 times, helping meet NICE 2023 guidelines
• Reduces care costs by over 90%, delivering measurable improvements in motor recovery at a fraction of the cost of traditional care (<10%), and reducing long-term disability and hospital re-admissions
• Improves workforce efficiency, allowing one therapist to oversee multiple patients simultaneously, saving 30–50% in staff time and reducing pressure on overstretched teams
• Delivers high patient satisfaction, with higher adherence and 87% reporting improved function, confidence or motivation using NeuroVirt at home or in clinic
• UKCA, FDA, CE approved/certified as software as a medical device. NeuroVirt is also ISO13485, ISO14001, DSPT, DTAC, DCB0129 certified
• 5+ jobs created and safeguarded, with a growing cross-functional team across clinical, technical, and commercial roles
• Key global partnerships include Guy's and St Thomas' amongst other NHS providers, Circle Health and Hobbs Rehabilitation amongst UK private rehabilitation providers and Mount Sinai, Cedars Sinai, John Hopkins and the Shirley Ryan Abilities Lab in the US
• Over $4.5M raised in non-dilutive and dilutive funding
• Selected for leading accelerator programmes, including Texas Medical Center Innovation, Endless Frontier Labs (NYC), KQLabs and Conception X
• NeuroVirt currently has an 100% lead conversion rate (as of May 2025)

“As proud investors, we believe NeuroVirt's XR solution is truly transformative for neurorehabilitation, significantly increasing access to vital therapy and empowering clinicians with real-time remote monitoring. This innovation represents a leap forward for the NHS, offering a scalable and affordable path to delivering more impactful rehabilitation and improving patient outcomes.”

October 2025